Cargando…

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report

BACKGROUND: Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs m...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Si-Cong, Ma, Dong-Heng, Zhong, Jia-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601004/
https://www.ncbi.nlm.nih.gov/pubmed/37900244
http://dx.doi.org/10.12998/wjcc.v11.i27.6579
_version_ 1785126103125327872
author Chen, Si-Cong
Ma, Dong-Heng
Zhong, Jia-Jian
author_facet Chen, Si-Cong
Ma, Dong-Heng
Zhong, Jia-Jian
author_sort Chen, Si-Cong
collection PubMed
description BACKGROUND: Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs may have synergistic effects, but evidence of which is lacking. CASE SUMMARY: Here, we report on a 73-year-old male, newly diagnosed with advanced esophageal squamous cell carcinoma (ESCC), who received a combination of toripalimab and anlotinib. Complete response was achieved after treatment for 3 mo and remission was maintained up to 14 mo. CONCLUSION: The combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted.
format Online
Article
Text
id pubmed-10601004
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-106010042023-10-27 Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report Chen, Si-Cong Ma, Dong-Heng Zhong, Jia-Jian World J Clin Cases Case Report BACKGROUND: Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs may have synergistic effects, but evidence of which is lacking. CASE SUMMARY: Here, we report on a 73-year-old male, newly diagnosed with advanced esophageal squamous cell carcinoma (ESCC), who received a combination of toripalimab and anlotinib. Complete response was achieved after treatment for 3 mo and remission was maintained up to 14 mo. CONCLUSION: The combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted. Baishideng Publishing Group Inc 2023-09-26 2023-09-26 /pmc/articles/PMC10601004/ /pubmed/37900244 http://dx.doi.org/10.12998/wjcc.v11.i27.6579 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Case Report
Chen, Si-Cong
Ma, Dong-Heng
Zhong, Jia-Jian
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
title Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
title_full Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
title_fullStr Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
title_full_unstemmed Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
title_short Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
title_sort combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601004/
https://www.ncbi.nlm.nih.gov/pubmed/37900244
http://dx.doi.org/10.12998/wjcc.v11.i27.6579
work_keys_str_mv AT chensicong combinationtherapywithtoripalimabandanlotinibinadvancedesophagealsquamouscellcarcinomaacasereport
AT madongheng combinationtherapywithtoripalimabandanlotinibinadvancedesophagealsquamouscellcarcinomaacasereport
AT zhongjiajian combinationtherapywithtoripalimabandanlotinibinadvancedesophagealsquamouscellcarcinomaacasereport